Cognoa is developing digital products intended to support healthcare providers in expediting diagnosis with the goal of improving access to timely intervention for children and families, starting with autism spectrum disorder (ASD).

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company focused on innovative approaches to driving durable behavior change in chronic disease, to positively impact health outcomes and cost of care. Dario creates durable behavior change in chronic conditions. For individuals facing the challenges of diabetes, prediabetes, hypertension, obesity, and other chronic conditions, Dario delivers highly personalized digital interactions, actionable data, engaging digital tools and easy to use monitoring devices plus human support. Combined, these touch points make doing the "right thing the easy thing" by encouraging proactive, positive behavior changes that lead to improved health outcomes. Dario chronic condition digital therapeutics solution and the MyDario™ mobile app is loved and recommended by close to 100,000 users around the globe--with a 4.9 star rating across 11,000 reviews on the Apple App Store, and world-class Net Promoter Score (NPS) of 77.

Cognoa seeks to help improve the lives and outcomes of children and their families living with behavioral health conditions. We strive to improve timely, equitable access to a diagnosis for caregivers with early concerns of developmental delay, including autism, to support opportunities for early intervention and improved outcomes for children and their families.